Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 09 03:07PM ET
2.58
Dollar change
+0.10
Percentage change
3.83
%
IndexRUT P/E- EPS (ttm)-0.03 Insider Own25.05% Shs Outstand204.94M Perf Week-16.40%
Market Cap549.90M Forward P/E- EPS next Y-0.37 Insider Trans2.56% Shs Float153.61M Perf Month81.34%
Income-22.77M PEG- EPS next Q-0.08 Inst Own69.54% Short Float10.26% Perf Quarter12.45%
Sales9.91M P/S55.49 EPS this Y61.46% Inst Trans-0.93% Short Ratio3.88 Perf Half Y-34.31%
Book/sh0.43 P/B5.94 EPS next Y-1.13% ROA-12.11% Short Interest15.75M Perf Year51.47%
Cash/sh0.74 P/C3.48 EPS next 5Y- ROE-114.77% 52W Range1.19 - 4.32 Perf YTD45.48%
Dividend Est.- P/FCF- EPS past 5Y-137.69% ROI-15.23% 52W High-40.39% Beta0.77
Dividend TTM- Quick Ratio5.51 Sales past 5Y129.39% Gross Margin86.98% 52W Low116.39% ATR (14)0.27
Dividend Ex-Date- Current Ratio5.51 EPS Y/Y TTM98.69% Oper. Margin-831.93% RSI (14)54.88 Volatility11.11% 13.78%
Employees52 Debt/Eq0.70 Sales Y/Y TTM-30.90% Profit Margin-229.67% Recom1.09 Target Price6.59
Option/ShortYes / Yes LT Debt/Eq0.68 EPS Q/Q89.77% Payout- Rel Volume0.39 Prev Close2.48
Sales Surprise2.79% EPS Surprise-15.34% Sales Q/Q-62.33% EarningsNov 13 AMC Avg Volume4.06M Price2.58
SMA204.55% SMA5022.40% SMA2004.81% Trades Volume1,366,653 Change3.83%
Date Action Analyst Rating Change Price Target Change
Jun-27-24Initiated BMO Capital Markets Outperform $5
Apr-09-24Initiated Piper Sandler Overweight $9
Feb-01-23Downgrade Jefferies Buy → Hold $14 → $1.50
Jan-27-23Downgrade Morgan Stanley Overweight → Equal-Weight $23 → $3
Nov-09-22Downgrade Goldman Buy → Neutral $16 → $3
Mar-09-22Initiated Robert W. Baird Outperform $26
Mar-01-22Initiated Wells Fargo Overweight $25
Feb-18-22Initiated SMBC Nikko Outperform $25
Dec-16-21Initiated Guggenheim Buy $28
Jul-16-21Initiated Needham Buy $45
Dec-06-24 08:00AM
Nov-14-24 12:51PM
02:16AM
Nov-13-24 05:15PM
04:01PM
08:00AM Loading…
Nov-06-24 08:00AM
Nov-01-24 04:30PM
Oct-22-24 08:00AM
Oct-16-24 03:42PM
Oct-14-24 12:00PM
Oct-04-24 08:01AM
Oct-03-24 04:55AM
Sep-26-24 08:00AM
Sep-06-24 08:00AM
Aug-12-24 09:10AM
08:01AM Loading…
08:01AM
Aug-05-24 08:00AM
Aug-02-24 08:00AM
Jul-05-24 08:00AM
Jun-26-24 09:14AM
08:36AM
07:41AM
Jun-25-24 06:34PM
Jun-18-24 07:30AM
07:02AM
Jun-13-24 06:00AM
Jun-12-24 07:00AM
Jun-07-24 08:00AM
Jun-03-24 04:31PM
04:17PM
03:11AM Loading…
May-15-24 03:11AM
May-14-24 08:57PM
05:15PM
05:03PM
04:01PM
May-07-24 04:05PM
May-03-24 04:05PM
May-02-24 10:01AM
08:00AM
Apr-29-24 01:37PM
Apr-15-24 05:30AM
Apr-05-24 08:00AM
Mar-20-24 11:19AM
08:01AM
Mar-19-24 08:53PM
04:01PM
Mar-14-24 04:26PM
Mar-01-24 05:08PM
Feb-29-24 08:00AM
Feb-15-24 04:01PM
Feb-02-24 08:00AM
Jan-31-24 02:23PM
Jan-22-24 08:00AM
Jan-15-24 09:30AM
Jan-10-24 08:00AM
Jan-05-24 08:00AM
Dec-19-23 07:30AM
Nov-29-23 08:00AM
Nov-15-23 02:00PM
12:52PM
Nov-14-23 06:35PM
04:08PM
Nov-07-23 08:00AM
Oct-24-23 08:00AM
Oct-10-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 04:01PM
Sep-05-23 09:55AM
Sep-04-23 03:04PM
Aug-24-23 08:00AM
Aug-15-23 01:54AM
Aug-14-23 07:02AM
07:00AM
Jul-31-23 08:00AM
Jul-18-23 07:08AM
Jun-28-23 08:00AM
Jun-15-23 08:00AM
Jun-05-23 08:00AM
May-19-23 12:54PM
08:00AM
May-16-23 11:41AM
May-12-23 10:15AM
May-11-23 04:01PM
May-04-23 08:00AM
Apr-27-23 04:52PM
Apr-15-23 08:24AM
Mar-30-23 06:08AM
Mar-28-23 04:01PM
Mar-15-23 04:01PM
Feb-14-23 05:32PM
Feb-08-23 05:42AM
Jan-31-23 04:01PM
Jan-24-23 02:32PM
Dec-19-22 02:05PM
Dec-16-22 06:19PM
Dec-01-22 09:55AM
Nov-29-22 04:01PM
Nov-08-22 07:00AM
Nov-03-22 08:26PM
Nov-02-22 07:00AM
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manning Paul B10% OwnerJun 27 '24Buy2.251,333,3332,999,9991,333,333Jul 01 08:00 AM